Lymphoma project report: current issues in treatment and research of AIDS-associated lymphomas (Part II of the oncology project) (Meeting abstract).

Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Lymphoma project report: current issues in treatment and research of AIDS-associated lymphomas (Part II of the oncology project) (Meeting abstract).

Proc Annu Meet Am Assoc Cancer Res; 14:A833 1995. Unique Identifier : AIDSLINE ICDB/95613985
Marco M; Treatment Action Group, New York, NY

Abstract: Objectives: to assess the current state of research on and current treatments for AIDS-associated lymphoma, and to recommend improvements. Methods: Current literature was reviewed and over 30 interviews were conducted with leading academic researchers, National Institutes of Health administrators, industry representatives, clinicians, treating physicians, and people with AIDS-associated lymphomas. Discussion: The etiology and pathogenesis of AIDS-associated lymphomas remain incompletely understood. Its incidence and prevalence are increasing as people survive longer due to improved opportunistic infection prophylaxis and treatment. Current therapy results in a CR rate of close to 50% but with a significant rate of relapse. Poor bone marrow reserve and the underlying HIV-associated immunodeficiency present a double challenge in treating these patients. Clinical trials evaluating new cytotoxic agents and pathogenesis based treatments (ie, cytokine modulators) in combination with antiviral therapy are essential. Optimal treatment remains to be defined. Conclusion: intensified efforts are needed to elucidate the etiology and pathogenesis of AIDS-associated lymphomas and to develop more effective treatment. Policy recommendations will be issued calling for better cooperation and collaboration between cancer cooperative groups, AIDS clinical trial networks, the pharmaceutical and biotechnology industries and treating physicians. We also recommend that research resources directed toward AIDS-associated lymphomas and other AIDS-associated malignancies be increased.

Keywords: Acquired Immunodeficiency Syndrome/DRUG THERAPY Antiviral Agents/THERAPEUTIC USE AIDS-Related Opportunistic Infections/DRUG THERAPY/PREVENTION & CONTROL Clinical Trials Human Incidence Lymphoma, AIDS-Related/EPIDEMIOLOGY/ETIOLOGY/MORTALITY/*THERAPY Prevalence Survival Rate ABSTRACT
951230
M95C3221

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .